BCAX
Bicara Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BCAX Profile
Bicara Therapeutics Inc.
A clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors
116 Huntington Avenue, Suite 703, Boston, MA 02116
--
Bicara Therapeutics Inc., was incorporated in Delaware on December 12, 2018. They are a clinical-stage biopharmaceutical company dedicated to bringing transformative bifunctional therapies to patients with solid tumors. Their main project, Alfa, is a bifunctional antibody that combines two clinically validated targets, epidermal growth factor receptor (EGFR) -directed monoclonal antibodies and a domain that binds human transforming growth factor β (TGF-b). Through this dual targeting mechanism, Alfa has the potential to exert powerful anti-tumor activity by simultaneously blocking the survival and proliferation of EGFR inherent in cancer cells, as well as immunosuppressive TGF-b signaling in the tumor microenvironment (TME). Ficerafusp alfa introduces TGF-b inhibitors directly into TME by binding to EGFR on tumor cells, which they believe will lead to a durable response and an increase in overall survival or OS, while reducing adverse reactions usually associated with systemic TGF-b inhibition.
